News Releases

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference

December 16, 2021

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

December 7, 2021

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study

October 26, 2021

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

October 6, 2021

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

October 1, 2021

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium

September 14, 2021

Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

September 7, 2021

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy

August 30, 2021

Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant

August 25, 2021

Latest News & Events

May 5, 2022

Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference

Read More...

Apr 28, 2022

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Read More...

Apr 6, 2022

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022

Read More...